PARESH C GIRI
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine
- Where
- YUCAIPA, CA
- NPI
- 1346497245
- Received
- $39,230 in 78 records, 2019 to 2025
- As principal investigator
- $155,161 of research payments to others in 55 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 10 | $4,930 |
| 2024 | General payment | 10 | $5,016 |
| 2023 | General payment | 4 | $2,604 |
| 2022 | General payment | 17 | $4,641 |
| 2021 | General payment | 5 | $5,179 |
| 2020 | General payment | 13 | $7,942 |
| 2019 | General payment | 19 | $8,915 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| United Therapeutics Corporation | 52 | $37,630 | 2019–2025 |
| Actelion Pharmaceuticals US, Inc. | 19 | $1,107 | 2019–2025 |
| Inari Medical, Inc. | 2 | $390 | 2022 |
| Merck Sharp & Dohme LLC | 2 | $48 | 2023–2025 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $29 | 2019–2020 |
| Genentech, Inc. | 1 | $24 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 26 | $35,724 |
| Food and Beverage | 50 | $2,530 |
| Consulting Fee | 1 | $970 |
| Education | 1 | $5 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-24 | United Therapeutics Corporation | $970 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-03 | United Therapeutics Corporation | $8 | Food and Beverage | In-kind items and services | Tyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-10-21 | Actelion Pharmaceuticals US, Inc. | $45 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2025 | |
| 2025-10-20 | United Therapeutics Corporation | $42 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-08 | United Therapeutics Corporation | $16 | Food and Beverage | In-kind items and services | Tyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-06-24 | United Therapeutics Corporation | $1,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-05-14 | United Therapeutics Corporation | $7 | Food and Beverage | In-kind items and services | Tyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-04-15 | United Therapeutics Corporation | $1,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-04-04 | Merck Sharp & Dohme LLC | $30 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-03-24 | United Therapeutics Corporation | $1,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2024-12-17 | United Therapeutics Corporation | $485 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-10-24 | United Therapeutics Corporation | $9 | Food and Beverage | In-kind items and services | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2024 | |
| 2024-10-06 | Actelion Pharmaceuticals US, Inc. | $102 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2024 | |
| 2024-10-06 | United Therapeutics Corporation | $28 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-07-08 | United Therapeutics Corporation | $1,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2024 | |
| 2024-06-30 | Actelion Pharmaceuticals US, Inc. | $100 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2024 | |
| 2024-04-30 | United Therapeutics Corporation | $1,698 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2024 | |
| 2024-04-29 | United Therapeutics Corporation | $24 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-01-24 | United Therapeutics Corporation | $1,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2024 | |
| 2024-01-18 | United Therapeutics Corporation | $28 | Food and Beverage | In-kind items and services | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2024 | |
| 2023-11-14 | United Therapeutics Corporation | $1,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYVASO Drug, PAH | 2023 | |
| 2023-10-25 | United Therapeutics Corporation | $1,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYVASO Drug, PAH | 2023 | |
| 2023-10-25 | Merck Sharp & Dohme LLC | $17 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-08 | United Therapeutics Corporation | $46 | Food and Beverage | In-kind items and services | TYVASO Drug, PAH | 2023 | |
| 2022-11-29 | United Therapeutics Corporation | $1,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYVASO Drug, PAH | 2022 | |
| 2022-11-29 | United Therapeutics Corporation | $23 | Food and Beverage | In-kind items and services | TYVASO Drug, PAH | 2022 | |
| 2022-11-17 | United Therapeutics Corporation | $2 | Food and Beverage | In-kind items and services | TYVASO Drug, PAH | 2022 | |
| 2022-10-17 | Actelion Pharmaceuticals US, Inc. | $55 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2022 | |
| 2022-10-16 | Actelion Pharmaceuticals US, Inc. | $144 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2022 | |
| 2022-10-16 | Actelion Pharmaceuticals US, Inc. | $72 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2022 | |
| 2022-10-15 | Actelion Pharmaceuticals US, Inc. | $120 | Food and Beverage | In-kind items and services | OPSUMIT Drug, Cardiology | 2022 | |
| 2022-10-15 | Actelion Pharmaceuticals US, Inc. | $120 | Food and Beverage | In-kind items and services | OPSUMIT Drug, Cardiology | 2022 | |
| 2022-09-01 | United Therapeutics Corporation | $4 | Food and Beverage | In-kind items and services | TYVASO Drug, PAH | 2022 | |
| 2022-07-08 | Inari Medical, Inc. | $34 | Food and Beverage | In-kind items and services | FLOWTRIEVER CATHETER, S Device, VTE | 2022 | |
| 2022-07-06 | Inari Medical, Inc. | $356 | Food and Beverage | In-kind items and services | FLOWTRIEVER CATHETER, S Device, VTE | 2022 | |
| 2022-07-06 | Actelion Pharmaceuticals US, Inc. | $23 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2022 | |
| 2022-04-22 | United Therapeutics Corporation | $1,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-04-01 | United Therapeutics Corporation | $102 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-03-09 | United Therapeutics Corporation | $1,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORENITRAM Drug, PAH | 2022 | |
| 2022-02-12 | Actelion Pharmaceuticals US, Inc. | $11 | Food and Beverage | In-kind items and services | OPSUMIT Drug, Cardiology | 2022 | |
| 2022-01-18 | United Therapeutics Corporation | $5 | Food and Beverage | In-kind items and services | TYVASO Drug, PAH | 2022 | |
| 2021-12-13 | Actelion Pharmaceuticals US, Inc. | $13 | Food and Beverage | In-kind items and services | OPSUMIT Drug, Cardiology | 2021 | |
| 2021-09-02 | United Therapeutics Corporation | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-09-02 | United Therapeutics Corporation | $125 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-09-01 | United Therapeutics Corporation | $1,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-06-29 | United Therapeutics Corporation | $1,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORENITRAM Drug, PAH | 2021 | |
| 2020-11-25 | Bayer Healthcare Pharmaceuticals Inc. | $15 | Food and Beverage | In-kind items and services | Adempas Drug, Cardio-pulmonary | 2020 | |
| 2020-11-11 | United Therapeutics Corporation | $1,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORENITRAM Drug, PAH | 2020 | |
| 2020-10-27 | United Therapeutics Corporation | $1,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORENITRAM Drug, PAH | 2020 | |
| 2020-05-28 | United Therapeutics Corporation | $870 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORENITRAM Drug, PAH | 2020 | |
| 2020-05-11 | United Therapeutics Corporation | $5 | Education | In-kind items and services | 2020 | ||
| 2020-05-01 | United Therapeutics Corporation | $114 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORENITRAM Drug, PAH | 2020 | |
| 2020-03-09 | Actelion Pharmaceuticals US, Inc. | $5 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2020 | |
| 2020-02-28 | United Therapeutics Corporation | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-02-27 | United Therapeutics Corporation | $103 | Food and Beverage | In-kind items and services | 2020 | ||
| 2020-02-27 | United Therapeutics Corporation | $10 | Food and Beverage | In-kind items and services | 2020 | ||
| 2020-02-24 | United Therapeutics Corporation | $840 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-01-30 | Actelion Pharmaceuticals US, Inc. | $12 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2020 | |
| 2020-01-14 | Actelion Pharmaceuticals US, Inc. | $124 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2020 | |
| 2019-12-23 | Bayer Healthcare Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | Adempas Drug, Cardio-pulmonary | 2019 | |
| 2019-12-13 | United Therapeutics Corporation | $3 | Food and Beverage | In-kind items and services | ORENITRAM Drug, PAH | 2019 | |
| 2019-12-13 | United Therapeutics Corporation | $2 | Food and Beverage | In-kind items and services | ORENITRAM Drug, PAH | 2019 | |
| 2019-11-18 | United Therapeutics Corporation | $840 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORENITRAM Drug, PAH | 2019 | |
| 2019-11-14 | United Therapeutics Corporation | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORENITRAM Drug, PAH | 2019 | |
| 2019-11-14 | United Therapeutics Corporation | $98 | Food and Beverage | In-kind items and services | ORENITRAM Drug, PAH | 2019 | |
| 2019-09-17 | Actelion Pharmaceuticals US, Inc. | $15 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2019 | |
| 2019-08-28 | Actelion Pharmaceuticals US, Inc. | $67 | Food and Beverage | In-kind items and services | OPSUMIT Drug, CARDIOVASCULAR DISORDERS | 2019 | |
| 2019-06-20 | United Therapeutics Corporation | $118 | Food and Beverage | In-kind items and services | ORENITRAM Drug, PAH | 2019 | |
| 2019-05-20 | Actelion Pharmaceuticals US, Inc. | $29 | Food and Beverage | In-kind items and services | BOSENTAN Drug, Pulmonary Hypertension | 2019 | |
| 2019-05-19 | Genentech, Inc. | $24 | Food and Beverage | In-kind items and services | Esbriet Biological, Immunology | 2019 | |
| 2019-04-23 | United Therapeutics Corporation | $840 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ORENITRAM Drug, PAH | 2019 | |
| 2019-03-24 | United Therapeutics Corporation | $5 | Food and Beverage | In-kind items and services | REMODULIN Drug, PAH | 2019 | |
| 2019-03-12 | Actelion Pharmaceuticals US, Inc. | $16 | Food and Beverage | In-kind items and services | OPSUMIT Drug, Cardiology | 2019 | |
| 2019-02-26 | United Therapeutics Corporation | $11 | Food and Beverage | In-kind items and services | ORENITRAM Drug, PAH | 2019 | |
| 2019-02-19 | United Therapeutics Corporation | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REMODULIN Drug, PAH | 2019 | |
| 2019-02-19 | United Therapeutics Corporation | $90 | Food and Beverage | In-kind items and services | REMODULIN Drug, PAH | 2019 | |
| 2019-01-22 | Actelion Pharmaceuticals US, Inc. | $25 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2019 | |
| 2019-01-10 | United Therapeutics Corporation | $111 | Food and Beverage | In-kind items and services | TYVASO Drug, PAH | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-15 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $180 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2025 |
| 2023-08-16 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $7,628 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RALINEPAG TO EVALUATE SAFETY AND EFFECTS ON EXERCISE CA | 2023 |
| 2023-05-19 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $420 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2023 |
| 2023-04-14 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $420 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2023 |
| 2023-03-17 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $420 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2023 |
| 2023-03-06 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $1,300 | A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION | 2023 |
| 2023-03-06 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $1,300 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2023 |
| 2023-03-06 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $1,300 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2023 |
| 2023-03-06 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $390 | A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION | 2023 |
| 2023-03-06 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $390 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2023 |
| 2023-03-06 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $1,300 | A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION | 2023 |
| 2023-02-03 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $7,500 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RALINEPAG TO EVALUATE SAFETY AND EFFECTS ON EXERCISE CA | 2023 |
| 2023-02-03 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $3,900 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RALINEPAG TO EVALUATE SAFETY AND EFFECTS ON EXERCISE CA | 2023 |
| 2022-11-23 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $1,681 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2022 |
| 2022-11-04 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $1,316 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2022 |
| 2022-07-18 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $1,699 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2022 |
| 2022-06-20 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $420 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2022 |
| 2022-05-23 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $1,699 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2022 |
| 2022-03-21 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $1,699 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2022 |
| 2022-02-16 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $1,950 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2022 |
| 2022-01-24 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $1,699 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2022 |
| 2021-11-23 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $2,539 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 |
| 2021-08-23 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $1,699 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 |
| 2021-06-21 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $420 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 |
| 2020-11-24 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $1,699 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-09-22 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $1,278 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-08-25 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $6,266 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-08-10 | Actelion Pharmaceuticals, Ltd | Loma Linda Univ Hlth | $1,300 | OPsumit Users Registry | 2020 |
| 2020-08-10 | Actelion Pharmaceuticals, Ltd | Loma Linda Univ Hlth | $200 | OPsumit Users Registry | 2020 |
| 2020-07-23 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $97 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-07-13 | Actelion Pharmaceuticals, Ltd | Loma Linda Univ Hlth | $28,375 | OPsumit Users Registry | 2020 |
| 2020-07-07 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $97 | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2020 |
| 2020-07-07 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $97 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-06-23 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $97 | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2020 |
| 2020-06-23 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $97 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-06-04 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $2,101 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-05-21 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $97 | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2020 |
| 2020-05-14 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $97 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-05-05 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $97 | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2020 |
| 2020-05-05 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $97 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-04-14 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $1,662 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-03-24 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $4,124 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-03-05 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $97 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-03-05 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $97 | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2020 |
| 2020-03-03 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $1,950 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-03-03 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $97 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-03-03 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $520 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-01-23 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $97 | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2020 |
| 2020-01-14 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $97 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-01-07 | United Therapeutics Corporation | LOMA LINDA UNIVERSITY HEALTH (LLUH) | $520 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2019-10-28 | Actelion Pharmaceuticals, Ltd | LOMA LINDA UNIVERSITY ADVENTIST HEALTH SCIENCES CTR | $13,100 | OPUS - AC-055-503 | 2019 |
| 2019-08-05 | Actelion Pharmaceuticals, Ltd | LOMA LINDA UNIVERSITY ADVENTIST HEALTH SCIENCES CTR | $20,900 | OPUS - AC-055-503 | 2019 |
| 2019-06-03 | Actelion Pharmaceuticals, Ltd | Loma Linda University | $12,625 | OPUS - AC-055-503 | 2019 |
| 2019-02-11 | Actelion Pharmaceuticals, Ltd | Loma Linda University | $12,600 | OPUS - AC-055-503 | 2019 |
| 2019-02-11 | Actelion Pharmaceuticals, Ltd | Loma Linda University | $1,300 | OPUS - AC-055-503 | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Yucaipa, CA, county San Bernardino County, CA, state California; placed by its city name.
| Measure | Place (city or town) Yucaipa, CA | County San Bernardino County, CA | State California |
|---|---|---|---|
| Population B01003 | 54,421 | 2,197,104 | 39,287,377 |
| Population, 2020 census P1 | 54,542 | 2,181,654 | 39,538,223 |
| Median age B01002 | 36.3 | 34.7 | 37.9 |
| Under 18 B01001 | 26.2% | 25.5% | 22.0% |
| 65 and over B01001 | 16.0% | 12.6% | 15.7% |
| Households B11001 | 18,506 | 674,915 | 13,548,091 |
| Foreign born B05002 | 10.7% | 21.6% | 27.0% |
| Median household income B19013 | $90,794 | $85,478 | $99,122 |
| Median family income B19113 | $108,424 | $93,416 | $113,346 |
| Per capita income B19301 | $39,987 | $34,343 | $49,513 |
| Poverty rate B17001 | 9.1% | 13.3% | 12.0% |
| Unemployment rate B23025 | 7.0% | 7.1% | 6.6% |
| Civilian labor force B23025 | 25,965 | 1,046,624 | 20,068,466 |
| Mean commute (minutes) B08013 | 32.6 | 32.6 | 28.7 |
| Bachelor's degree or higher B15003 | 26.9% | 23.3% | 37.1% |
| Housing units B25001 | 19,248 | 743,886 | 14,644,735 |
| Owner-occupied B25003 | 73.4% | 62.1% | 55.9% |
| Renters B25003 | 26.6% | 37.9% | 44.1% |
| Median home value B25077 | $502,100 | $505,000 | $734,700 |
| Median gross rent B25064 | $1,711 | $1,801 | $2,036 |
| White, not Hispanic B03002 | 53.9% | 24.7% | 33.8% |
| Black B03002 | 1.1% | 7.5% | 5.2% |
| Hispanic or Latino B03002 | 36.3% | 55.2% | 40.2% |
| Asian B03002 | 3.2% | 8.1% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.3% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Yucaipa, CA.
Comments